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metastatic melanoma and the compiling evidence that the use
of oncolytic viruses can enhance cancer immunotherapies tar-
geted against various immune checkpoint proteins has at-
tracted great interest in the field of cancer virotherapy. We
have developed a novel platform for clinically relevant envel-
oped viruses that can direct the virus-induced immune
response against tumor antigens. By physically attaching tu-
mor-specific peptides onto the viral envelope of vaccinia virus
and herpes simplex virus 1 (HSV-1), we were able to induce a
strong T cell-specific immune response toward these tumor an-
tigens. These therapeutic peptides could be attached onto the
viral envelope by using a cell-penetrating peptide sequence
derived from human immunodeficiency virus Tat N-terminally
fused to the tumor-specific peptides or, alternatively, therapeu-
tic peptides could be conjugated with cholesterol for the attach-
ment of the peptides onto the viral envelope. We used two
mouse models of melanoma termed B16.OVA and B16-F10
for testing the efficacy of OVA SIINFEKL-peptide-coated
viruses and gp100-Trp2-peptide-coated viruses, respectively,
and show that by coating the viral envelope with therapeutic
peptides, the anti-tumor immunity and the number of tu-
mor-specific CD8+ T cells in the tumor microenvironment
can be significantly enhanced.
INTRODUCTION
Cancer immunotherapy aims to increase both the activity and the
amount of tumor infiltrating tumor-specific T effector cells in order
to elicit therapeutic efficacy. The T effector cells, named CD8+
T cells, more specifically cytotoxic T cell lymphocytes (CTLs), are
critical components of protective anti-tumor immunity. The tumor-
specific CTLs can be found in tumor tissue, and a positive correlation
between the amount of tumor-infiltrating CTLs and patient survival
has been observed.1–5 A recent approval of antibodies targeting im-
mune checkpoint molecules, such as programmed death 1 (PD-1),
programmed death ligand 1 (PD-L1), and cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4), which block the negative feedbackMolecula
This is an open access article under the CC BY-NC-Nsystems within the tumormicroenvironment to activate the pre-exist-
ing anti-tumor immune responses, have met tremendous clinical
excitement.6 The use of these immune checkpoint inhibitor (ICI) an-
tibodies can create durable responses in 10%–20% of cancer patients.7
The common feature of the patients responding to ICI therapy is that
they have an existing anti-tumor immunity and CTL infiltration in
the tumor tissue already prior to ICI therapy.8,9 However, the remain-
ing 80%–90% of the patients are not responding due to the lack of
anti-tumor immune responses or other immune-suppressive aspects
of the tumor microenvironment, presenting a strong rationale on
finding novel combinational therapies that attract tumor-specific
CD8+ T cells into tumors to increase the number of responders to
ICI therapies.
Oncolytic viruses are natural pathogens that have been selected or de-
signed to specifically infect and kill cancer cells. They are able to kill
cancer cells by two different mechanisms: (1) by direct cell lysis (i.e.,
oncolysis) of the infected cells and (2) by inducing a strong anti-viral
immune response against the therapeutic virus to eliminate the path-
ogen and in some instances the host cells they infect.10 Virus-induced
tumor apoptosis and/or necrosis releases large amounts of tumor-
associated proteins that are normally not accessible to antigen-pre-
senting cells. This release of tumor antigens coupled with the virus-
associated danger signaling drives antigen cross-presentation by
tumor-associated dendritic cells (DCs) in the tumor-draining lymph
nodes.11–13 A major weakness of the oncolytic viruses currently used
in the clinics is that while they induce a strong anti-viral immune
response, the anti-tumor immune response remains modest at best
and thus reduces the therapeutic effect of these viruses.14 To over-
come this problem and to significantly increase the anti-tumorr Therapy Vol. 26 No 9 September 2018 ª 2018 The Authors. 2315
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. A Schematic Presentation of a PeptiENV-Cancer Vaccine Platform
Anti-tumor immunity-inducing peptides can readily be attached into the envelope of clinically relevant oncolytic enveloped viruses, e.g., HSV-1 and vaccinia viruses. Various
different peptides including MHC class I and II epitopes can be delivered by PeptiENV-platform for inducing potent activation of antigen-presenting cells and consequently
increased T cell-specific immunological responses.
Molecular Therapyimmune response of current oncolytic enveloped viruses, we devel-
oped a method for coating tumor-specific peptides directly onto
the viral envelope (peptide-coated oncolytic-enveloped viruses
[PeptiENV]). Our results show that this is an effective strategy to in-
crease the amount of tumor-specific T cells in the tumor microenvi-
ronment, and as compared to genetically engineered viruses coding
for tumor-specific antigens, this approach is highly suitable for the
next generation of personalized approaches that rely on the identifi-
cation of patient-specific neo-antigens to be used in cancer immuno-
therapy. The PeptiENV approach is suitable for all enveloped viruses
used in the clinics to enhance their tumor-specific T cell responses.RESULTS
Enveloped Viruses Can Be Coated with Therapeutic Peptides by
Using Cell-Penetrating Peptide Sequence or Cholesterol Moiety
as an Anchor
The outer membrane of all enveloped viruses consists of host-derived
lipid bilayer.15 We hypothesized that therapeutic peptide sequences
could be attached into the viral envelope by using a cell-penetrating
peptide (CPP) sequence or peptide-conjugated cholesterol as attach-
ment moieties (see Figure 1 for a schematic presentation of the
PeptiENV platform).
Various CPP sequences tested were able to anchor the therapeutic
peptides into the viral envelope (data not shown), and a CPP
sequence derived from HIV Tat protein was chosen to be used as a
representative of CPP anchoring. Interestingly, cholesterol conju-
gated to the N terminus but not to the C terminus of the therapeutic
peptides was suitable for anchoring the peptides into the viral enve-
lope as assayed by ELISA (Figure 2A). We went on to confirm the
complex formation of fluorescein isothiocyanate (FITC)-labeled
C-terminally conjugated peptides more quantitatively by using flow
cytometry and found that both attachment moieties were capable
of forming virus-peptide complexes with envelope-labeling effi-
ciencies of 67.6% and 46.9% for CPP and cholesterol moieties,
respectively (Figure S1).2316 Molecular Therapy Vol. 26 No 9 September 2018We further analyzed the CPP anchoring by surface plasmon reso-
nance in order to get an insight of the binding affinities and the
number of peptides bound to the viral envelope. Surface plasmon
resonance (SPR) analysis showed that the affinity of the CPP moiety
toward both the vaccinia virus (VACV) and herpes simplex virus 1
(HSV-1) envelope was very high, and it also seems that the binding
is two sided for both envelopes, where most probably, the first inter-
action is depicting the electrostatic interaction and the second, the
penetration of the moiety into the envelope. Interestingly, the Koff
was very low, indicating a very strong interaction between the
CPP moiety and the viral envelope. The binding was almost
completely dependent on the CPP moiety, as the same peptide
without the CPP moiety did not have significant affinity toward
either of the viral envelopes (Figures 2B and 2C). We also estimated
the number of peptides bound to one viral particle, and for HSV-1, it
was estimated to be approximately 11,000 peptides and for VACV,
which is the bigger of the two viruses, approximately 35,000 peptides
(data not shown).
Viruses Coated with Therapeutic Peptides Retain Oncolytic
Potential
The degree of lytic cell killing caused by the spread of the infection in a
panel of cell lines was monitored using a colorimetric cell-viability
assay (Figure 3). The coating of the viral envelope with therapeutic
peptides did not have any adverse effect on the oncolytic efficacy
on any of the cell lines tested, and the efficacy was found to be similar
to the naked virus. The therapeutic peptides alone did not have any
toxicity toward the cell lines tested.
Therapeutic Peptides Are Readily Cross-Presented by Antigen-
Presenting Cells
Next, we investigated whether the CPP- or cholesterol-containing
therapeutic peptides used in the PeptiENV platform enable
the neo-epitope SIINFEKL to be cross-presented on major
histocompatibility complex (MHC) class I molecules by the anti-
gen-presenting cells. Mouse DC line Jaws II was pulsed with
GRKKRRQRRRPQRWEKISIINFEKL, cholesterol-CSIINFEKL, or
Figure 2. Physicochemical Characterization of PeptiENV Complexes
(A) ELISA characterization of different C- and N-terminal conjugation strategies to attach FITC-labeled anti-tumor peptides into the viral envelope. An anti-virus antibody was
coated to the bottom of 96-well plate, and PeptiENV complexes were incubated in the wells. After washing the unbound fraction, an anti-FITC HRP-conjugated antibody was
used for the detection of the PeptiENV complexes. Each bar is themean ± SEM of technical triplicates. (B) Surface plasmon resonance analysis of the interaction between the
CPP Tat peptide and HSV-1 envelope. (C) Surface plasmon resonance analysis of the interaction between the CPP Tat peptide and VACV envelope.
www.moleculartherapy.orgSIINFEKL peptide alone, and the efficiency of cross-presentation of
the mature form of the neo-epitope (SIINFEKL) from these different
peptides was assessed by flow cytometry (Figure 4A). Interestingly,
SIINFEKL from the cholesterol-conjugated peptide was cross-pre-
sented by only 11% of the Jaws II cells after 4 hr of incubation, likely
indicating a compromised processing by the immunoproteasome. In
striking contrast, SIINFEKL from the CPP-containing peptide was
cross-presented with high efficiency as 89% of Jaws II cells were cross
presenting the epitope. SIINFEKL peptide alone was cross-presented
by 38% of the Jaws II cells. Since SIINFEKL peptide can be directly
loaded to the MHC class I complex without the need for immunopro-
teasome processing, the cross-presentation kinetics might be faster
than with peptides processed by the immunoproteasome and thus
the cross-presentation at 4 hr may be too late to see the optimal
cross-presentation efficiency of the SIINFEKL peptide.16
Antigen-Presenting Cells Can Efficiently Present Therapeutic
Peptides Delivered by PeptiENV
Next, we tested whether PeptiENV platform can deliver therapeutic
peptides to antigen-presenting cells and if they can cross-present
the MHC class I epitope from these peptides. PeptiENV viruses
coated with GRKKRRQRRRPQRWEKISIINFEKL or cholesterol-
CSIINFEKL was used to infect bone marrow-derived DCs (BMDCs)
for 4 hr, and the cross-presentation efficacy of the neo-epitope
(SIINFEKL) was assessed by flow cytometry (Figure 4B). As expected,
the efficacy of SIINFEKL cross-presentation from PeptiENV coated
with cholesterol-conjugated SIINFEKL peptide was low, as only
8.3% of BMDCs were shown to cross-present the epitope. In contrast,
SIINFEKL was efficiently cross-presented from PeptiENV coated
with CPP-conjugated SIINFEKL peptide, as more than 44% of
BMDCs were shown to cross-present the SIINFEKL epitope. Since
the drastic difference of SIINFEKL cross-presentation efficacy by
the PeptiENV coated with cholesterol-conjugated SIINFEKL peptide
as compared to the PeptiENV coated with CPP-conjugated
SIINFEKL peptide, we chose CPP conjugation as the strategy to an-
chor therapeutic peptides in the PeptiENV platform.Vaccination with PeptiENV Induces a Strong Immune Response
against MHC Class I Epitopes Coated into the Viral Envelope
To further validate the PeptiENV platform, we tested whether this
platform can induce a robust T cell-specific immune response in
naive mice toward the MHC class I restricted epitopes presented by
the PeptiENV viruses. To this end, we vaccinated naive C57BL/
6JOlaHsd mice with bivalent PeptiENV coated with SIINFEKL-
and SVYDFFVWL-containing peptides (OVA/Trp2-PeptiENV).
After the vaccination, mice were analyzed for the induction of oval-
bumin (OVA)- and tyrosinase-related protein-2 (Trp2)-specific
T cell responses by the interferon-gamma enzyme-linked immuno-
spot (ELISPOT) (Figure 5). Vaccination with OVA and Trp2 peptides
alone did not induce any SIINFEKL- or SVYDFFVWL-specific T cell
response. By striking contrast, bivalent OVA/Trp2-PeptiENV was
able to induce a robust SIINFEKL- as well as SVYDFFVWL-specific
T cell response. These responses were of similar magnitude as the
T cell-specific response toward the VACV used within the platform,
indicating a very high immune response toward the attached MHC
class I restricted epitopes.
PeptiENV Elicits Potent Anti-tumor Efficacy and Induces Robust
Infiltration of Tumor-Specific CD8+ Effector T Cells in a
Syngeneic Mouse Model of B16.OVA Melanoma
To study the anti-tumor efficacy of PeptiENV platform, we used a
well-established syngeneic mouse melanoma model B16 expressing
chicken OVA as a model antigen.17 When mice bearing B16.OVA
tumors were treated intratumorally with OVA-targeted PeptiENV
(OVA-PeptiENV VACV), VACV, peptides alone, or vehicle
(mock), we observed significant reduction in tumor growth in
OVA-PeptiENV group as compared to all other treatment groups.
We set a tumor size threshold of 250 mm3 for defining the responders
in each treatment group. Treating mice with SIINFEKL peptide alone
did not have any effect on tumor growth, and none of the mice were
responsive to the therapy (Figure 6A). In virus- and mock-treated
groups, there was one responder in each group accounting
for 14.3% of response rate (Figures 6B and 6C). In contrast,Molecular Therapy Vol. 26 No 9 September 2018 2317
Figure 3. Oncolytic Potency of PeptiENV Is Not Affected by the Attachment of Anti-tumor Peptides into the Viral Envelope
The oncolytic properties of PeptiENV with vaccinia, vaccinia virus, and anti-tumor peptide alone were compared in five cancer cell lines using multiplicities of infection 1, 0.1,
0.01, and 0.001. After 3 days post-infection, the amount of living cells were measured and compared to the viability of uninfected cells. Each bar is the mean ± SEM of
technical triplicates.
Molecular TherapyOVA-PeptiENV treatment was very efficient in controlling tumor
growth, with a response rate of 71.4% for this group (Figure 6D).
Although B16 murine melanoma is not permissive for human
HSV-1 infection,18,19 omitting the anti-tumor effect of direct lysis
by productive HSV-1 replication in the tumor, we wanted to test
whether we could see an indication of direct induction of tumor-spe-
cific T cell response by the PeptiENV platform (now used as a cancer
vaccine). When mice bearing B16.OVA tumors were treated intratu-
morally with OVA-PeptiENV HSV-1, HSV-1 alone, or vehicle
(mock), we observed a favorable but non-significant trend toward
higher reduction of tumor growth in the OVA-PeptiENV HSV-1
group as compared to the HSV-1 or mock groups, with response rates
of 0%, 12.5%, and 28.6% for mock, HSV-1, and OVA-PeptiENV
HSV-1 groups, respectively (Figures 6E–6G). We went on to analyze
whether there were any differences in the infiltration of tumor-specific
CD8+ T cells between the treatment groups and whether enhanced
infiltration of tumor-specific CD8+ T cells into the tumor microenvi-
ronment was accountable for the superior anti-tumor efficacy seen in
the OVA-PeptiENV VACV group and for the favorable trend seen in
the OVA-PeptiENVHSV-1 group (Figure 6H). As expected, we saw a
significantly higher number of tumor-specific T cells infiltrated into
the tumors of OVA-PeptiENV VACV-treated mice as compared to
the tumors of VACV-, peptide alone-, or mock-treated mice. Indeed,
treating mice with VACV did not result in significantly increased tu-2318 Molecular Therapy Vol. 26 No 9 September 2018mor-specific CD8+ T cell infiltration to the tumor as compared to
mock (0.76-fold increase over mock). In striking contrast, OVA-
PeptiENV VACV treatment was able to increase tumor-specific
CD8+ T cell infiltration into the tumor by 6-fold as compared to
mock. We also saw a significantly higher number of tumor-specific
T cells infiltrated into the tumors of OVA-PeptiENV HSV-1-treated
mice as compared to the tumors of HSV-1- or mock-treated mice.
As expected, HSV-1 treatment alone was not able to induce tumor-
specific CD8+ T cell infiltration into the tumor, most likely the reason
being the non-permissive nature of B16.OVA for HSV-1 infection and
lysis. In contrast, OVA-PeptiENVHSV-1 treatment was able to signif-
icantly increase tumor-specific CD8+ T cell infiltration into the tumor
as compared toHSV-1 alone ormock.We also analyzed the number of
virus-specific T cells in the tumors of VACV- and OVA-PeptiENV
VACV-treated groups, and no significant difference between the
groups was seen (Figure 6I). The superior anti-tumor efficacy of
OVA-PeptiENV VACV treatment was translated into significantly
longer survival, with median survival of 35 days as compared to 22,
27, and 25 days with OVA peptide alone, VACV, and mock groups,
respectively (Figure 6J). The observed favorable trend toward higher
reduction of tumor growth in OVA-PeptiENV HSV-1 group trans-
lated into a clear but non-significant trend toward longer survival,
with a median survival of 32 days as compared to 25 and 22 days
with HSV-1 alone and mock groups, respectively (data not shown).
Figure 4. Antigen-Presenting Cells Can Readily Cross-Present Ovalbumin
MHC Class I Epitope SIINFEKL from Peptides Used in a PeptiENV Platform
(A) Mouse dendritic cell line Jaws II was pulsed with N-terminal cholesterol-conju-
gated PeptiENV peptide containing SIINFEKL, N-terminal CPP Tat fusion containing
SIINFEKL, or SIINFEKL alone. Cross-presentation was determined by flow
cytometry using APC-conjugated anti-H-2Kb bound to SIINFEKL. (B) Mouse bone-
marrow-derived dendritic cells were infected with purified PeptiENV viruses com-
plexed with peptides described in (A). Cross-presentation was determined by flow
cytometry using APC-conjugated anti-H-2Kb bound to SIINFEKL. Each bar is the
mean ± SEM of technical triplicates.
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Effector T Cells in a Syngeneic Mouse Model of B16-F10
Melanoma
Finally, we tested the PeptiENV platform in B16-F10 melanoma, a
representative model of an aggressive and poorly immunogenic tu-
mor.20–22 B16-F10 cells express endogenous tumor antigens Trp2
and glycoprotein 100 (gp100).23 Viruses were coated with MCH-I-
restricted epitopes Trp2180–188 and gp10025–33-containing peptides
(Trp2/gp100-PeptiENV). When the tumors reached approximately
150 mm3 is size, mice were treated intratumorally with the bivalent
gp100/Trp2-PeptiENV VACV, VACV, or vehicle (mock). We chose
to start the treatments when the tumors were considerably big and the
immunosuppressive tumor microenvironment already efficiently es-
tablished (resembling the situation that is found in many humanmel-
anomas) to test the PeptiENV platform in very challenging condi-
tions.24 Because of the aggressive nature of the B16-F10 model and
the large size of the initial tumors, we set the tumor size threshold
to 450 mm3 for defining the responders in each treatment group.
The mock-treated group did not respond to therapy, and all mice
in this group developed large tumors very rapidly. In contrast, treat-
ment with gp100/Trp2-PeptiENV VACV or VACV alone suppressed
the growth of the tumors and, in both groups, 14.3% of mice were
defined as responders (Figures 7A–7C). The low number of re-
sponders was expected, taking into account the high starting volume
of the tumors (150 mm3) and the poorly immunogenic phenotype of
the B16-F10 model. We went on to study whether there were any dif-
ferences in the infiltration of tumor-specific T cells between the
groups and whether the PeptiENV platform was able to enhance
the infiltration of tumor-specific CD8+ T cells into the tumor micro-
environment in these highly immunosuppressive conditions. Treat-ing mice with VACV alone did not result in increased gp100-specific
CD8+ T cell infiltration into the tumor as compared to mock. In
contrast, gp100/Trp2-PeptiENV VACV treatment significantly
increased tumor infiltration of gp100-specific CD8+ T cells over
5-fold when compared to VACV alone or mock groups (Figure 7D).
Trp2-specific CD8+ T cells were found more abundantly infiltrated
into the tumors in all groups, although similarly to the gp100-specific
CD8+ T cells, the highest number of Trp2-specific CD8+ T cells was
found in the tumors of gp100/Trp2-PeptiENV VACV-treated mice
with over 4-fold increase as compared to mock (Figure 7E).
DISCUSSION
In this study, we show that by coating the viral envelope with immu-
nostimulatory peptides, such as MHC class I-restricted tumor-associ-
ated epitopes, we were able to exploit the superior immunostimula-
tory properties of viruses in eliciting a robust immune response
toward the cancer itself. As the attachment moiety for coating the
therapeutic peptides onto the viral envelope, we chose the CPP
sequence of HIV Tat protein fused to the N terminus of the tumor
epitopes. The CPP portion of the therapeutic peptides did not influ-
ence the presentation of the tumor epitopes from these peptides by
antigen-presenting cells, and when vaccinating naive mice with biva-
lent PeptiENV targeting both OVA and Trp2 epitopes we saw robust
T cell-specific immune response against both epitopes. We also
showed using two different mouse models of melanoma termed
B16.OVA (expressing chicken OVA as a model antigen) and B16-
F10 (a cancer model for an aggressive and poorly immunogenic tu-
mor) that by treating tumor-bearing mice with OVA-PeptiENV or
gp100/Trp2-PeptiENV, respectively, we were able induce robust infil-
tration of tumor-specific T cells into the tumors of treated mice.
Although we acknowledge that the OVA is a foreign antigen, in these
settings it could be used as model antigen for approximate assessment
of neo-antigen immune responses.25,26 This novel platform could be
used with a multitude of enveloped viruses already used in the clinics,
such as HSV-1-based talimogene laherparepvec (T-VEC; Imlygic
from Amgen), which has already been approved by the US Food
and Drug Administration and the European Medicines Agency for
the treatment of metastatic melanoma,27 or viruses in ongoing
advanced clinical trials, such as an oncolytic VACV, the pexastimo-
gene devacirepvec (Pexa-Vec), currently tested for the treatment of
hepatocarcinoma.28 Compared to a variety of other approaches, the
clear advantage of this platform is that by introducing the anti-tumor
immunity-inducing peptides non-genetically into the clinically
approved, good manufacturing practice (GMP)-grade viruses, one
can react very quickly to changes in patients’ MHC class I-restricted
tumor antigens simply by coating the virus with a new set of tumor-
specific peptides.
Since the recent approval of immunotherapeutic antibodies targeting
immune checkpoint molecules such as CTLA-4, PD-1, and PD-L1,
there has been a new wave of interest in using oncolytic viruses in
combination with ICIs. The first indication of synergistic effects on
anti-tumor activity by a combination of oncolytic virus with check-
point inhibitor antibodies was seen in a phase I study using T-VECMolecular Therapy Vol. 26 No 9 September 2018 2319
Figure 5. Bivalent PeptiENV Targeting OVA and Trp2 Can Induce Robust T Cell-Specific Immune Response toward Both Tumor Epitopes
Naive C57BL/6J mice (n = 3/group) were immunized with purified PeptiENV complexed with both OVA- and Trp2-containing peptides or with peptides alone on days 1, 2, 3,
and 10. Six days after the last treatment, mice were sacrificed and spleens were collected for the quantification of activated interferon-gamma (IFN-g) secreting CD8+
cytotoxic T cells specific for the two tumor epitopes (SIINFEKL and SVYDFFVWL) by using a mouse interferon-gamma ELISPOT assay. Each bar is the mean ± SEM of six
technical repeats and biological triplicates.
Molecular Therapyin combination with a checkpoint inhibitor ipilimumab (a therapeu-
tic antibody targeted against CTLA-4) and was later confirmed in a
follow-up phase II study showing a significant increase in confirmed
objective response rate by the immune-related response criteria
(irRC) with the T-VEC + ipilimumab compared with ipilimumab
alone (39% versus 18%, respectively; p = 0.002).29,30 Recently, Ribas
et al.31 showed in a phase IB study using T-VEC combined with a
checkpoint inhibitor pembrolizumab (a therapeutic antibody targeted
against PD-1) high overall and complete response rates of 62% and
33%, respectively, in patients with advanced melanoma. The authors
reported that intratumoral injections of T-VEC alone increased CD8+
T cell infiltration in patients responding to combination therapy,
indicating a virus-induced beneficial change in the tumor microenvi-
ronment, although the number of virus-specific CD8+ T cells was not
analyzed. It is intriguing to hypothesize that by using T-VEC in the
PeptiENV platform, one could further enhance the number of tu-
mor-specific CD8+ T cells and thus further increase the anti-tumor
efficacy of the combination therapy. Our group has earlier shown
that treatment of melanoma by oncolytic adenoviruses coated with
MHC class I restricted tumor-associated antigen peptides increases
the number of tumor-specific CD8+ T cells as compared to naked
adenovirus, and the increase of tumor-specific CD8+ T cells also in-
creases the number of responders to the combination therapy with
ICIs.16,32 The PeptiENV platform also enables the use of different
MHC class II epitopes coated onto the viral envelope to boost
CD4+ T cell responses alone or in combination with MHC class I epi-
topes. Another important aspect of the platform is that the selected
virus needs to go through the rigorous quality control and approval
stages only once, reducing time and costs of entering into clinical
testing with a new set of therapeutic peptides. In contrast, platforms
with genetically modified viruses need to go through every stage of
approval every time a new modification or a new peptide or protein
is introduced, making it virtually impossible to use these platforms
in truly personalized settings.
In summary, by using therapeutic enveloped viruses as active, multi-
functional adjuvants for the therapeutic anti-tumor peptides, we can2320 Molecular Therapy Vol. 26 No 9 September 2018combine the advantages of both approaches; viruses activate effi-
ciently the immune response and induce immunogenic cell death of
the tumor cells by lysis, and the therapeutic anti-tumor peptides
direct the immune response toward the tumor-associated antigens.
As more personalized cancer therapies are needed for enhanced
anti-tumor efficacy, there is a rationale to convert the existing immu-
novirotherapy modalities into more personalized and targeted ap-
proaches. The PeptiENV platform can convert existing clinically rele-
vant enveloped viruses into multimodal personalized cancer vaccines
without the need for genetic modifications.
MATERIALS AND METHODS
Cell Lines
Human lung carcinoma cell line A549, human triple-negative breast
cancer cell line MDA-MB-436, African Green monkey kidney epithe-
lial cell line Vero and murine melanoma cell line B16-F10 were
cultured in RPMI with 10% fetal bovine serum (FBS) (Life Technol-
ogies), 1% L-glutamine, and 1% penicillin and streptomycin at 37C/
5% CO2. The cell line B16.OVA,
17 a mouse melanoma cell line ex-
pressing chicken OVA, was kindly provided by Prof. Richard Vile
(Mayo Clinic, Rochester, MN, USA). B16.OVA cells were cultured
in DMEM with 10% FBS (Life Technologies), 1% L-glutamine, and
1% penicillin and streptomycin at 37C/5% CO2. Murine DC line
Jaws II was cultured in alpha minimum essential medium with 20%
FBS (Life Technologies), ribonucleosides, deoxyribonucleosides,
4 mM L-glutamine (Life Technologies), 1 mM sodium pyruvate
(Life Technologies), and 5 ng/mL murine GM-CSF (PeproTech,
USA) at 37C/ 5% CO2. Murine breast cancer cell line 4T1 was
cultured in RPMI with 10% FBS (Life Technologies), 1% L-glutamine,
and 1% penicillin and streptomycin at 37C/5% CO2. All cell lines
excluding B16.OVA were purchased from ATCC and were not
further authenticated. All cells in culture were routinely tested for my-




Figure 6. PeptiENV Targeting OVA Elicits Potent Anti-tumor Efficacy and Induces Robust Infiltration of Tumor-Specific CD8+ Effector T Cells into the Tumor
in a Syngeneic Mouse Model of B16.OVA Melanoma
(A–F) Tumor growth curves for each mouse/group are shown. C57BL/6 mice were inoculated subcutaneously in right flank with 3.5  105 B16.OVA melanoma cells and
treated on days 11,13, and 19 with (C) OVA-PeptiENV VACV (n = 7), (B) VACV (n = 7), or (A) injection media alone as mock (n = 7), and in experiments using HSV-1 within the
platform, mice were treated on days 10,12, and 18 with (F) OVA-PeptiENV HSV-1 (n = 7), (E) HSV-1 (n = 8), or (D) injection media alone as mock (n = 6). A threshold of
250 mm3 was set to define the percentage of mice responding to the different therapies (dotted line). The percentage of responders in each treatment group is shown on the
right side of the dotted line. (G) The number of CD19CD3+CD8+ tumor-infiltrating lymphocytes were evaluated for tumor antigen specificity (SIINFEKL-pentamer) for each
group and plotted as fold increase over the mock group. (H) The number of CD19CD3+CD8+ tumor-infiltrating lymphocytes were evaluated for virus antigen specificity
(vaccinia-pentamer) for the OVA-PeptiENV VACV and VACV groups. (I) Kaplan-Meier survival curve for the OVA-PeptiENV VACV experiment. The median survival for each
group is shown in the parentheses. Data shown asmean ± SEM. **p < 0.01; ns., not significant (one-way ANOVA or unpaired t test for H). Flow cytometry was performedwith
three biological replicates and two technical replicates from each sample.
www.moleculartherapy.orgTEW-FITC were purchased from Pepscan (Lelystad, the Netherlands),
and an MHC class I-restricted epitope from chicken OVA SIINFEKL
(OVA257–264), an MHC class I-restricted epitope from tyrosinase-
related protein 2 SVYDFFVWL (TRP2180–188), GRKKRRQRRRP
QRWEKISIINFEKL, GRKKRRQRRRPQRWEKISVYDFFVWL, and
GRKKRRQRRRPQRWEKIKVPRNQDWL (having human gp100
[gp10025–33] MHC class I-restricted epitope embedded) were purchased
from Zhejiang Ontores Biotechnologies (Zhejiang, China).
Viruses
Western reserve strain of VACV coding for mouse DNA-dependent
activator of interferon (IFN)-regulatory factors (mDAIs)33 was pro-
duced in A549 cells and purified through 36% sucrose cushion ultra-centrifugation and eluted in 1 mM Tris (pH 9.0). Herpes simplex
virus type 1 (HSV-1) LoxLUC,34 a 17+ derivative, whose genome
carried an inserted cassette with a luciferase gene under a human
cytomegalovirus promoter (HSV-1(17+) LoxLUC) was produced
and tittered in Vero cells as previously described.34
PeptiENV Complex Formation
Peptides were mixed with either VACV or HSV-1 in plain
DMEM and incubated at 37C for 15 to 20 min for peptide-virus
complexes to form. After complex formation, PeptiENV was either
used directly or unbound peptides were removed by ultracentrifuga-
tion (20,000 g, 50 min) through 36% sucrose cushion in 1 mM Tris
(pH 9.0) prior experimentation.Molecular Therapy Vol. 26 No 9 September 2018 2321
Figure 7. Bivalent PeptiENV Targeting gp100 and Trp2 Induces Robust Infiltration of Tumor-Specific CD8+ Effector T Cells into the Tumor in a Syngeneic
Mouse Model of B16-F10 Melanoma
(A–C) Tumor growth curves for each mouse/group are shown. C57BL/6 mice were inoculated subcutaneously in right flank with 1 105 B16-F10 melanoma cells, and mice
were treated on days 10, 11, 12, 13, 17, and 18 with (C) gp100/Trp2-PeptiENV VACV (n = 7), (B) VACV (n = 7), or (A) injection media alone as mock (n = 5). A threshold of
450 mm3 was set to define the percentage of mice responding to the different therapies (dotted line). The percentage of responders in each treatment group is shown on the
right side of the dotted line. The percentage of CD19 CD8+ tumor-infiltrating gp100-specific CD8+ T cells (D) and CD19 CD8+ tumor-infiltrating Trp2-specific CD8+ T cells
(E) of the total number of CD19 CD8+ cells were assessed for each group. Data shown as mean ± SEM. *p < 0.05 (one-way ANOVA). Flow cytometry was performed with
three biological replicates and two technical replicates from each sample.
Molecular TherapyGeneration of BMDCs
2  106 bone marrow cells isolated from C57BL/6JOlaHsd mouse
were seeded in 10 mL complete medium (RPMI-1640) (Sigma) con-
taining 10 ng/mL recombinant granulocyte-macrophage colony-
stimulating factor (PeproTech), 10% FBS (Sigma), 2 mM L-glutamine
(Gibco), 50 U/mL penicillin, and 50 mg/mL streptomycin (Life Tech-
nologies). Cells were cultured at 37C in a humidified atmosphere of
5% CO2. On day 3, 10 mL of complete medium was added, and on
days 6 and 8, 9 mL of media was gently aspirated and replaced with
10 mL of fresh complete medium. Following 10 days of culture,
DCs were harvested and used for cross-presentation experiments
described below.
ELISAs
2.5  107 plaque-forming units (PFU) of VACV particles were com-
plexed with GRKKRRQRRRPQRVRRALISLEQLESIINFEKLTEW-
FITC (CPP-peptide-FITC) or cholesterol-CRVRRALISLEQLESIIN
FEKLTEW-FITC (cholesterol-conjugated peptide-FITC) in 100 mL
of DMEM for 15 min at 37C. After complexation, unbound peptides
were removed by ultracentrifugation (20,000  g, 50 min) through
36% sucrose cushion in 1 mMTris (pH 9.0). For ELISA, anti-vaccinia
polyclonal antibody (ab21039, Abcam) was coated overnight at 4C2322 Molecular Therapy Vol. 26 No 9 September 2018into Nunc maxisorb 96-well immunoplates (Thermo Fisher) at the
concentration of 2 mg/mL. VACV-peptide complexes were incubated
for 30–60 min at 37C or room temperature (RT) and washed with
1 PBS three times. Complexes were detected with anti-FITC anti-
body conjugated to horseradish peroxidase (ab19224, Abcam)
(1:5,000 dilution in 2% BSA-PBS).
2.5 107 PFU of HSV-1 particles were complexed with CPP-peptide-
FITC or cholesterol-conjugated peptide-FITC in 100 mL of DMEM
for 15 min at 37C. For ELISA, anti-HSV-1 polyclonal antibody
(ab19946, Abcam) was coated overnight at 4C into maxisorb
96-well immunoplates at the concentration of 2 mg/mL. HSV-1-pep-
tide complexes were incubated for 30–60 min at 37C or RT and
washed with 1 PBS three times. Complexes were detected with
anti-FITC antibody conjugated to horseradish peroxidase (ab19224,
Abcam) (1:5,000 dilution in 2% BSA-PBS).Cross-Presentation Experiments
For peptide cross-presentation experiments, 1.6  106 Jaws II cells
were incubated with 50 nmol of GRKKRRQRRRPQRWEKISIIN
FEKL, cholesterol-CSIINFEKL, or SIINFEKL peptide. After 4 hr of
www.moleculartherapy.orgincubation, cells were washed and stained with either allophycocya-
nin (APC)-conjugated anti-mouse H-2Kb bound to SIINFEKL
(141606, BioLegend) or APC-conjugated mouse IgG k isotype Ctrl
(400119, BioLegend), and the samples were analyzed by flow cytom-
etry. For PeptiENV cross-presentation experiments, 15 nmol of either
GRKKRRQRRRPQRWEKISIINFEKL or cholesterol-CSIINFEKL
were complexed with 4.8 107 PFU of VACV, and after the complex-
ation, unbound peptides were removed by ultracentrifugation
(20,000  g, 50 min) through 36% sucrose cushion in 1 mM Tris
(pH 9.0), and the purified viral pellets were suspended in 100 mL of
complete RPMI-1640. 2  106 BMDCs were plated in 2 mL of com-
plete RPMI-1640 media and were infected with the purified
PeptiENV viruses. After 4 hr of incubation, cells were washed and
stained with either APC-conjugated anti-mouse H-2Kb bound to
SIINFEKL (141606, BioLegend) or APC-conjugated mouse IgG k iso-
type Ctrl (400119, BioLegend), and the samples were analyzed by flow
cytometry.
Cell Viability Assay
50,000 cells were plated in a 96-well plate 1 day prior to infections.
Three days post-infection cell viability was measured using the The
CellTiter-Fluor Cell Viability Assay (Promega), and a multi-well plate
reader (Varioscan; ThermoLabsystems) was used to determine the
fluorescence of the samples.
Surface Plasmon Resonance
Measurements were performed using a multi-parametric SPR Navi
220A instrument (Bionavis, Tampere, Finland). PBS (pH 7.4) was
used as a running buffer. A constant flow rate of 20 mL/min was
used throughout the experiments, and temperature was set
to +20C. Laser light with a wavelength of 670 nm was used for sur-
face plasmon excitation. A sensor slide with a silicon dioxide surface
was activated by 5 min of plasma treatment followed by coating with
APTES ((3-aminopropyl)triethoxysilane) by incubating the sensor in
50 mM APTES in isopropanol for 4 hr. The sensor was then washed
and placed into the SPR device, and viruses were immobilized in situ
on the sensor surface of the two test channels by injecting approxi-
mately 1.1  107 PFU of VACV or 5.5  107 PFU of HSV-1 in
PBS (pH 7.4) for 12 min, followed by a 3-min wash with PBS.
CPP-containing anti-tumor peptide or peptide without CPP sequence
(a non-interacting control) was then injected into both flow channels
of the flow cell in parallel, with increasing concentrations ranging
from 1.2 mM to 100 mM.
Animal Experiments
All animal experiments were reviewed and approved by the Experi-
mental Animal Committee of the University of Helsinki and the Pro-
vincial Government of Southern Finland (license number ESAVI/
9817/04.10.07/2016).
For vaccination experiments, 8- to 9-week-old immune competent
female naive C57BL/6JOlaHsd mice were injected on days 0, 1, 2,
and 9 with 2  106 PFU of purified bivalent OVA/Trp2-PeptiENV
VACV-containing tumor antigens SIINFEKL (OVA257–264) andSVYDFFVWL (TRP2180–188) or SIINFEKL and SVYDFFVWL-con-
taining peptides alone. Untreated mice were used as a mock group.
Six days after the last treatment, mice were sacrificed and spleens
were collected for immunological analysis. C57BL/6JOlaHsd mice
were obtained from Scanbur (Karlslunde, Denmark). For PeptiENV
melanoma experiments with VACV as a viral backbone, 8- to
9-week-old immune-competent female C57BL/6JOlaHsd mice were
injected in the right flank with 350,000 B16.OVA melanoma cells,
and when the tumor size reached approximately 50 mm3 (11 days af-
ter injection), mice were treated with 2 106 PFU of VACV, 2 106
PFU of OVA-PeptiENV VACV, peptides only, or injection media
only (mock). Mice were treated on days 11 and 13, and a booster
treatment was given on day 19. For PeptiENV experiments with
HSV-1 as a viral backbone, 8- to 9-week-old immune-competent fe-
male C57BL/6JOlaHsd mice were injected in the right flank with
350,000 B16.OVA melanoma cells, and when the tumor size reached
approximately 50 mm3 (10 days after injection), mice were treated
with 5  106 PFU of HSV-1, 5  106 PFU of OVA-PeptiENV
HSV-1, or injection media only (mock). Mice were treated on days
10 and 12 and a booster treatment was given on day 18. In
B16.OVA experiments, mice were considered as responders when
the tumor volume at the time of final measurement remained less
than five times the initial volume. For PeptiENV B16-F10 melanoma
experiments, 8- to 9-week-old immune-competent female C57BL/
6JOlaHsd mice were injected in the right flank with 100,000 B16-
F10 melanoma cells, and when the tumor size reached approximately
150 mm3 (11 days after injection), mice were treated with 2  106
PFU of sucrose cushion-purified VACV, 2  106 PFU of sucrose
cushion-purified gp100/Trp2-PeptiENV VACV, or injection media
only (mock). Since the initial tumors were of considerably large in
size, mice were treated on days 10, 11, 12, and 13, and booster treat-
ments were given on days 17 and 18. In B16-F10 experiments, mice
were considered as responders when the tumor volume at the time
of final measurement remained less than three times the initial vol-
ume. In all experiments, tumors were measured every second or third
day until the tumor size reached the maximum allowed, and mice
were then sacrificed and tumors collected. For all mouse models,
n R 7 was considered adequate for performing statistical analysis.
Animals were excluded from the experiments only if tumors failed
to form or they were too big before starting the experiment or if health
concerns were reported. For all animal experiments, mice were
randomly grouped and during the experiments, and the measure-
ments for tumor size were done blinded for the groups.
ELISPOT Assays
The amount of SIINFEKL (OVA257–264), SVYDFFVWL (TRP2180–188)
and VACV-specific activated, interferon-g secreting T cells were
measured by ELISPOT assay (CTL, Ohio USA) according to the man-
ufacturer’s instructions. Briefly, 2 mg of SIINFEKL peptide or
SVYDFFVWL peptide was used to stimulate the antigen-presenting
cells (NB. these peptides contained only the MHC class I epitope in
order to be able to rule out any unspecific stimulation which could
derive from CPP Tat sequence or immunoproteasome processing
sequence used in the PeptiENV platform). After 3 days of stimulation,Molecular Therapy Vol. 26 No 9 September 2018 2323
Molecular Therapyplates where stained and sent to CTL-Europe GmbH for counting of
the spots.
Flow Cytometry
The following antibodies were used in the experiments: TruStain Fc
block anti-mouse and anti-human CD16/32 (101320, BioLegend),
FITC anti-mouse CD8 (A502-3B-E, ProImmune), phycoerythrin-
cyanin 7 (PE/Cy7) anti-mouse CD3e (100320, BioLegend), PE/Cy7
anti-mouse CD19 (115520, BioLegend), FITC anti-mouse CD11c
(553801, BD Bioscience), APC anti-mouse H-2Kb bound to
SIINFEKL (141606, BioLegend), APC mouse IgG (usually mouse
IgG) k isotype Ctrl (400119, BioLegend). SIINFEKL epitope-specific
T cells were studied using R-PE-labeled H-2Kb/SIINFEKL pentamer
(F093-84A-E, ProImmune). Trp2(180–188) epitope-specific T cells
were studied using R-PE-labeled H-2Kb/SVYDFFVWL pentamer
(F185-2B-E, ProImmune), and gp100(25–33) epitope-specific T cells
were studied using APC-labeled H-2Kb/KVPRNQDWL pentamer
(F1333-4B-E, ProImmune).
Flow cytometric analyses were performed using a Gallios flow cytom-
eter (Beckman Coulter) or BD Accuri 6C plus flow cytometer (BD
Biosciences). FlowJo software v10 (FlowJo) was used for the data
analysis.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 6.0 software
(GraphPad Software, USA). For tumor growth curve analysis, two-
way ANOVA was used, and p < 0.05 was considered statistically sig-
nificant. For flow cytometry data analysis, one-way ANOVA or un-
paired t test were used. All results are expressed as the mean ± SEM.
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